REGN · Q3 2025 Earnings

Cautious

Regeneron Pharmaceuticals

Reported October 28, 2025

30-second summary

Total revenue grew just 1% YoY to $3.754B as EYLEA U.S. fell 41% to $681M and EYLEA HD U.S. reached $431M (+10% YoY vs. $392M in Q3 2024; +10% QoQ per Marion). Combined retina franchise revenue declined 28% YoY. Management lowered SG&A, COCM, CapEx, and GAAP gross-margin guidance — but the GAAP effective tax rate quietly stepped from an 11–13% range to a ~14% point estimate, a hidden cut that partly offsets the ~$125M opex reduction at midpoint. The bull case remains conditional on a late-November RVO/four-week PDUFA, a late-December alternative-vial-filler PDUFA, and the linvoseltamab launch — none of which are de-risked on this print.

Headline numbers

EPS

Q3 FY2025

$11.83

Revenue

Q3 FY2025

$3.75B

+1.0% YoY

Gross margin

Q3 FY2025

82.0%

Operating margin

Q3 FY2025

27.4%

Key financials

Q3 FY2025

Metric	Q3 FY2025	YoY	Q2 FY2025	QoQ
Revenue	$3.75B	+1.0%	$3.68B	+2.1%
EPS	$11.83	—	$12.89	-8.2%
Gross margin	82.0%	—	83.0%	-100bps
Operating margin	27.4%	—	29.4%	-196bps

Guidance

Operating cost guidance tightened and lowered across R&D, SG&A, COCM, and CapEx, but GAAP tax rate elevated to ~14% from 11–13% range; gross margin GAAP reduced 1pt to 82%.

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

Changes to prior guidance

Metric	Period	Prior guide	New guide	Δ	Result
GAAP R&D	FY 2025	$5.660–$5.790 billion	$5.680–$5.750 billion	Low end +$20M, high end -$40M; midpoint lowered $10M	Lowered
GAAP SG&A	FY 2025	$2.810–$2.940 billion	$2.775–$2.845 billion	Low end -$35M, high end -$95M; midpoint lowered $65M	Lowered
Non-GAAP SG&A	FY 2025	$2.450–$2.550 billion	$2.400–$2.450 billion	Low end -$50M, high end -$100M; midpoint lowered $75M	Lowered
GAAP gross margin on net product sales	FY 2025	Approximately 83%	Approximately 82%	-1 percentage point	Lowered
COCM	FY 2025	$1.000–$1.050 billion	$950 million–$1.000 billion	Low end -$50M, high end -$50M; midpoint lowered $50M	Lowered
Capital expenditures	FY 2025	$880–$950 million	$850–$890 million	Low end -$30M, high end -$60M; midpoint lowered $45M	Lowered
GAAP effective tax rate	FY 2025	11%–13%	Approximately 14%	Point estimate raised to 14% (above prior range of 11–13%)	Lowered
Non-GAAP effective tax rate	FY 2025	11%–13%	Approximately 12%	Range narrowed and midpoint raised slightly to ~12%	Raised

Reaffirmed unchanged this quarter: Non-GAAP R&D ($5.150–$5.200 billion), Non-GAAP gross margin on net product sales (Approximately 86%)

Segment KPIs

Q3 FY2025

Segment	Q3 FY2025	YoY
EYLEA HD - U.S.	$0.431B	+10.0%
EYLEA - U.S.	$0.681B	-41.0%
Total EYLEA HD and EYLEA - U.S.	$1.112B	-28.0%
Libtayo - Global	$0.365B	+26.0%
Praluent - U.S.	$0.067B	+26.0%
Evkeeza - U.S.	$0.043B	+34.0%
Sanofi Collaboration Revenue	$1.617B	+28.0%
Bayer Collaboration Revenue	$0.345B	-12.0%

Other KPIs

Q3 FY2025

Segment	Q3 FY2025
Dupixent Global Net Sales	$4.86 billion
EYLEA HD U.S. Net Sales	$431 million
Total Gross Margin on Net Product Sales	82%
Non-GAAP Gross Margin on Net Product Sales	86%
Operating Income	$1,026.8 million
R&D Expenses (Non-GAAP)	$1,349.9 million
Share Repurchases	$663 million
Dividend per Share	$0.88

Management tone

Narrative arc: Catalent procedural delay (Q2) → New filler submitted, PDUFA stack reset to late-Nov/late-Dec/Jan (Q3) — only two quarters of context are available, so a full multi-quarter arc isn't constructed here. The transcript signal available from Q&A (no prepared-remarks tone analysis was provided) carries the read:

Manufacturing has moved from "third-party procedural" to "this is structurally our problem to fix." In Q2, Len framed the Catalent issue as procedural deficiencies for Novo Nordisk to resolve. This quarter, asked by BMO's Evan Seegerman about internal regulatory changes, Len pivoted the answer away from regulatory teams and squarely onto filling capability: "Primary issue is manufacturing — specifically filling capabilities. Own filling plant expected to come online in 2026." He also acknowledged FDA scrutiny is elevated industry-wide and that other large pharmas are absorbing similar CRLs without disclosure. The shift signals management now expects filler dependency to remain a CRL risk through 2026 — and the $7B+ in-house build is the answer, not a workaround.

The PDUFA stack has fragmented into three sequential bets. Tyler Van Buren (TD Cowen) extracted the new timeline: late-November PDUFA for RVO/four-week dosing, late-December for an alternative vial filler, and a January 2026 pre-filled syringe resubmission. Len's closer — "it's not over until it's over" — is a meaningful step down in confidence from Q2's "favorable action expected once filling is resolved." Each PDUFA is now a discrete approval risk, and a miss on any extends the EYLEA-to-EYLEA-HD transition by another quarter.

Linvoseltamab is being positioned as the new pipeline anchor with more concrete commercial signal. Len explicitly cited "up to 10 registrational trials" and the ~$30B myeloma TAM (same framing as Q2), but Marion added launch-execution evidence — formulary listings, pathway inclusions, REMS completion, payer coverage — and George cited a 100% ORR in smoldering (now 19 patients with molecular CR in the 1-year-followed subset) plus 83% ORR as monotherapy in newly diagnosed myeloma. The story has progressed from "early data + intent" to "early data + launch infrastructure," but no revenue contribution is in the print.

On ILEA pricing, management refused to engage. Akash Tiwari (Jefferies) pressed on volume-based discounting tactics; Marion declined on competitive sensitivity, framing EYLEA HD growth as efficacy/durability/safety driven. The silence itself reads as confirmation that price/rebate dynamics are material and unfavorable.

Q&A highlights

Akash Tiwari · Jefferies

What ground-level commercial strategies is Regeneron using on ILEA, particularly regarding volume-based discounts to gain share from competitors? Are there price pressures on both ILEA and ILEA-HD? Should volume and revenue gains continue ahead of label enhancements?

Management declined to answer specific questions about competitive strategy, rebates, and ground-level tactics, citing competitive sensitivity. Marion noted that ILEA-HD growth is driven by clinical efficacy, safety, and durability. Provided guidance that sequential demand growth for ILEA-HD should be moderate to high single digits pending label enhancements, and similar demand reductions expected for ILEA in Q4.

ILEA-HD unit demand grew 18% quarter-over-quarterILEA-HD now represents approximately 40% of U.S. retina franchiseILEA-HD net sales grew 10% quarter-over-quarter to $431 millionILEA net sales decreased 10% quarter-over-quarter to $681 million

Evan Seegerman · BMO Capital Markets

What internal changes has Regeneron made to its regulatory and manufacturing teams to prevent recent CRLs and ensure products reach patients more quickly?

Len Schleifer stated that regulatory issues are not internal; the team includes former FDA employees and experienced industry veterans with strong FDA relationships. Primary issue is manufacturing—specifically filling capabilities. Own filling plant expected to come online in 2026. Acknowledged FDA scrutiny is higher now but noted other large companies face similar filler issues without publicizing CRLs. Backup fillers are complicated due to FDA requirements for equipment, stability testing, and quality assurance.

Regeneron's in-house filling plant expected online in 2026Over $7 billion investment plan in manufacturing facilities in New York and North CarolinaFDA inspections require detailed equipment mapping, stability testing, and quality validation for each fillerMultiple large pharma companies experience similar filler-related CRLs but don't publicize them

Tyler Van Buren · TD Cowan

What is the probability of approval for the late December PDUFA decision on the RVO and four-week dosing filing with the new filler? Is this the same filler used for the Libtayo adjuvant CSCC approval?

Len stated this is a different filler than used for Libtayo adjuvant CSCC. Approval timeline depends on FDA inspection and review of new filler. Ideally if filler approved before November PDUFA date for RVO/four-week dosing, could wrap up then. If approval takes until December, would resubmit immediately after. Management believes no other approvability issues remain; only filler approval needed. Emphasized uncertainty: 'it's not over until it's over.'

PDUFA date for RVO/four-week dosing application in late NovemberAlternative vial filler application submitted with PDUFA date in late DecemberPlan to submit pre-filled syringe application with alternate filler by January 2026 (four-month FDA review)Management believes label and indication discussions with FDA already resolved

Brian Abrahams · RBC Capital Markets

For the Factor XI antibody program, what is Regeneron looking for from the Phase II AFib study and what would need to be demonstrated to move into registrational trials in that and other large indications?

George Yancopoulos explained Phase II AFib is a run-in to Phase III pivotal program. Strategy focuses on benefit-risk ratio, with bleeding reduction potentially more important than anticoagulation magnitude. Regeneron believes two distinct antibodies enable customized patient treatment—one with least bleeding risk for at-risk patients, another with higher anticoagulation capability when needed. Major opportunities seen beyond SPAF where bleeding concerns currently limit anticoagulant use. Management positioning this as a future-focused strategy.

Two distinct Factor XI antibodies being developed for tailored anticoagulation therapyPhase II AFib study is run-in to Phase III pivotal programPivotal studies in postoperative VTE following total knee replacement ongoing, data expected 2027Regeneron Roundtable on Factor XI scheduled November 10 with new clinical data in catheter-associated thrombosis and provoked subclinical GI bleeding

Chris Schott · JPMorgan

How is the Linazific launch progressing versus expectations, and when could it move into earlier lines of therapy? Can timelines be accelerated through FDA discussions?

Marion reported launch progressing very favorably with positive physician feedback, strong formulary listings, pathway inclusions, REMS completion, and payer coverage. Early days but 'very, very good' progress. George outlined aggressive program expansion into first-line, second-line, and pre-malignant myeloma settings, with unprecedented efficacy data (100% ORR in smoldering, molecular complete responses in amyloidosis). Len emphasized Regeneron planning up to 10 registrational trials, 30B market potential, and commitment to collaborate with FDA to accelerate. Regeneron Roundtable on Linazific scheduled December 2025.

Linazific approved for fifth-line multiple myeloma; launch off to strong start100% objective response rate in smoldering myeloma (19 patients), 100% molecular complete response in subset followed 1+ yearPhase III head-to-head study vs. Darzalex in smoldering myeloma planned83% overall response rate as monotherapy in newly diagnosed myeloma

Answers to last quarter's watch list

Catalent filling resolution and revised EYLEA HD PDUFA dates — Partially answered, mostly negatively. Regeneron has resubmitted with an alternative vial filler (late-December PDUFA) and is targeting January 2026 for pre-filled syringe resubmission with a four-month review. The original Catalent path appears effectively abandoned in favor of the in-house plant coming online in 2026. Status: Resolved negatively.

EYLEA + EYLEA HD U.S. combined revenue trajectory — Combined Q3 revenue of $1.112B declined 28% YoY. EYLEA HD's +10% QoQ growth ($431M) was overwhelmed by EYLEA U.S. -41% YoY ($681M). Marion guided to further sequential EYLEA declines in Q4. Status: Resolved negatively.

Branded anti-VEGF segment dynamics — Management declined to give a refreshed segment-share number this quarter. Status: Continue monitoring.

Libtayo adjuvant CSCC approval (October 2025 PDUFA) — Approved; global Libtayo revenue grew 26% YoY to $365M in Q3 ahead of the indication expansion contributing meaningfully. Status: Resolved positively.

Linvoseltamab myeloma readouts — Launched in fifth-line MM with strong early infrastructure traction; smoldering MM data (100% ORR, 19 patients; molecular CR in the 1-year subset) and 83% monotherapy ORR in newly diagnosed announced. Up to 10 registrational trials planned, Phase III head-to-head vs. Darzalex confirmed. Status: Resolved positively.

Itepekimab COPD path — Management did not provide an update on the call exchanges captured; the program's status remains unresolved on this print. Status: Continue monitoring.

What to watch into next quarter

Late-November RVO/four-week dosing PDUFA and late-December alternative-vial-filler PDUFA — these are now sequential, discrete approval events. A clean stack would unlock EYLEA HD label enhancements; a miss on either pushes commercial inflection past Q1 2026.

EYLEA + EYLEA HD U.S. combined trajectory toward Q4 — Marion guided to further sequential EYLEA U.S. declines and only moderate-to-high-single-digit HD sequential growth. Watch whether combined Q4 prints below $1.05B (which would mark a new low and a third consecutive quarter of worsening YoY decline).

GAAP effective tax rate — now ~14% for FY2025, raised from the prior 11–13% range. Watch for any 2026 commentary; another step-up would compress GAAP EPS into 2026 even if opex savings persist.

Pre-filled syringe resubmission filed by January 2026 — slippage of this resubmission would extend the four-month review window and delay the most commercially important EYLEA HD format.

Linvoseltamab early launch metrics — first dollar-revenue disclosure, prescriber breadth, and any earlier-line trial initiation pace against the "up to 10 registrational trials" target.

Itepekimab COPD decision — whether Regeneron/Sanofi commit to a confirmatory COPD trial or formally deprioritize after the AERIFY-2 miss.

Sources

Regeneron Q3 2025 press release (Exhibit 99.1): https://www.sec.gov/Archives/edgar/data/872589/000087258925000026/exhibit991q32025.htm
Regeneron Q3 2025 earnings call Q&A (transcript-derived)

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.